VENETOCLAX | N208573 | ABBVIE INC
| Trial # | Patent | Type | Petitioner | Status | Filed | Decision |
|---|---|---|---|---|---|---|
| IPR2023-00052 | 11110087 | IPR | Dr. Reddy's Laboratories, Inc. et al. | Final Written Decision | 2022-10-14 | 2025-01-30 |
| PGR2022-00023 | 10993942 | PGR | Dr. Reddy's Laboratories, Inc. et al. | Final Written Decision | 2022-02-03 | 2025-01-30 |
| Case | Court | Filed | Status | Judge |
|---|---|---|---|---|
| D.N.J. | 2020-07-22 | Terminated 2020-08-28 | — |
Source: PACER. NOS 835 (Patent - Abbreviated New Drug Application).
| Patent # | Expiration | PED | Drug Substance | Drug Product | Use Code | Delist |
|---|---|---|---|---|---|---|
| 8546399 | Jun 27, 2031 | — | Yes | Yes | — | — |
| 8722657 | Jan 29, 2032 | — | Yes | — | — | — |
| 9174982 | May 26, 2030 | — | — | — | — | |
| 9539251 | Sep 6, 2033 | — | — | — | — | |
| 10730873 | Nov 21, 2031 | — | Yes | — | — | — |
| 10993942 | Sep 6, 2033 | — | — | — | — | |
| 11110087 | Sep 6, 2033 | — | — | — | — | |
| 11369599 | May 23, 2032 | — | — | Yes | — | — |
| 11413282 | Sep 6, 2033 | — | — | — | — | |
| 11590128 | Sep 6, 2033 | — | — | — | — |
| Code | Date | Status |
|---|---|---|
| ODE-239 | May 15, 2026 | Expired |
VENCLEXTA (venetoclax) received an AB therapeutic equivalence rating, indicating FDA-assessed bioequivalence to reference products.
New: AB
VENCLEXTA (venetoclax) received an AB therapeutic equivalence code, indicating the FDA considers it therapeutically equivalent to reference products.
New: AB
VENCLEXTA (venetoclax) receives therapeutic equivalence rating AB, indicating bioequivalence to the reference product and permitting generic substitution.
New: AB